Skip to Main Content

Paper Details

Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial.
Oncologist
2
2022
Author NameAffiliation
Fang-Shu OuMayo Clinic
Matthew B YurgelunDana-Farber Cancer Institute
Deborah SchragDana-Farber Cancer Institute
  • 1 - 3

Datasets

Release 1.2